# glp 1 cost effectiveness

A cross-cut look at new analyses shows how grievance rhetoric can legitimize illiberal policies, while medical findings favor nuance over absolutes. Replication challenges an SSRI “super-responder” claim, adjusted data find no link between prenatal opioids and ASD/ADHD, and modeling argues GLP-1s may be cost-effective for knee osteoarthritis with obesity. Rising solar activity beyond expected cycles, alongside diet–gum health links and tumor-targeted immunotherapy, underscores the need to update models and policies quickly.